Results 151 to 160 of about 226,969 (309)

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]

NPJ Breast Cancer
Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching PA, Schneeweiss A, Maurer C.   +52 more
europepmc   +1 more source

Procedural Outcome of Modern Percutaneous Coronary Intervention in Proximal Chronic Total Occlusions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Long‐term outcome in patients with chronic total occlusions (CTO) depends on the target vessel and proximity of the lesion. Aims To investigate of the target vessel was associated with procedural efficacy and safety in patients with proximal CTO lesions.
Emil N. Holck, Guiseppe Vadalá, Mohamed Ayoub, Sevket Gorgulu, Alexandre Avran, Gerald S. Werner, Kambis Mashayekhi, Nihat Kalay, Omer Goktekin, Jaroslaw Wojcik, Myron Zaczkiewicz, Roberto Garbo, Juergen Arenz, Jörg Dalibor, Bas Schölzel, Nicolas Boudou, Michael Behnes, Pierfrancesco Agostoni, Carlo Di Mario, Roberto Diletti, Juan Luis Guitiérrez‐Chico, Evald H. Christiansen   +21 more
wiley   +1 more source

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. [PDF]

Future Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

A Novel 3D Wiring Technique—ZOLUTION Zero Degree OverLap View Universal Three DimensIONal CTO Wiring

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT We present a novel simple and easy‐to‐use 3D wiring technique for coronary chronic total occlusions (CTOs) named ZOLUTION—Zero OverLap View Universal Three dimensIONal wiring. ZOLUTION can be used for: (1) Distal cap puncture, (2) CTO body wiring, (3) Retrograde wiring, and (4) Reverse controlled antegrade and retrograde tracking (reverse CART)
Eugene B. Wu, Calvin Leung, Wataru Nagamatsu, Kambis Mashayekhi, Shunsuke Matsuno, Scott A. Harding, Sidney Lo, Soo Teik Lim, Lei Ge, Ji‐Yan Chen, Jie Qian, Seung‐Whan Lee, Hsien‐Li Kao, Arun Kalyanasundaram, Muenpetch Muenkaew, Henry Jian‐Fang Luo, Emmanouil S. Brilakis   +16 more
wiley   +1 more source

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer. [PDF]

NPJ Breast Cancer
Van Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, Blohmer J, Treue D, Schmatloch S, Lehmann A, Hanusch C, Link T, Sers C, Bjelic-Radisic V, Hummel M, Huober J, Schmitt WD, Fasching PA, Aktas B, Rhiem K, Reinisch M, Nekljudova V, Denkert C, Loibl S.   +24 more
europepmc   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. [PDF]

Future Oncol
Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T.   +24 more
europepmc   +1 more source

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends

Clinical Pharmacology &Therapeutics, EarlyView.
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling.
Jason Boer, Ellen Cannady, Filip Cuyckens, Ulrike Glaenzel, Camille Granvil, Felix Huth, Alexander D. James, Wenying Li, Céline Veau, Graeme Young, Qin Yue, Gregory S. Walker, Upendra A. Argikar, Jonathan N. Bauman, Cathy Cantalloube, Yu‐Luan Chen, Ping Kang, Patricia Moliner, Mette L. Pedersen, Isabel Piel, Simone Schadt, Hanno Schieferstein, Julia Suchomel, Shuai Wang, S. Cyrus Khojasteh   +24 more
wiley   +1 more source

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. [PDF]

ERJ Open Res
Mukherjee M, Tan NS, Huang C, Kim B, Radford K, Ju X, Venegas Garrido C, Kjarsgaard M, Rodríguez-Suárez E, Wechsler ME, Walker B, Börjesson Sjö L, Necander S, Ashkar A, Weidner J, Sehmi R, McCrae C, Khalidi N, Nair P.   +18 more
europepmc   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source